CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | |
| 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | |
| 4 Filing | 2026-01-26 | English | |
| 4 Filing | 2026-01-05 | English | |
| 4 Filing | 2026-01-05 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 9417631 | FORM 8-K | 2025-11-24 | English | ||
| 9417632 | FORM S-3 | 2025-11-07 | English | ||
| 9417635 | FORM 8-K | 2025-11-05 | English | ||
| 9417633 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
| 9417634 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
LigaChem Biosciences Inc.
Clinical-stage biopharma developing ADCs, immuno-oncology d…
|
141080 | KR | Professional, scientific and te… |
|
Linical Co., Ltd.
A global CRO providing a full spectrum of drug development …
|
2183 | JP | Professional, scientific and te… |
|
Lipigon Pharmaceuticals AB
A clinical-stage company developing therapeutics for lipid-…
|
LPGO | SE | Professional, scientific and te… |
|
Lipum AB
Clinical-stage biopharma developing novel treatments for ch…
|
LIPUM | SE | Professional, scientific and te… |
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Clinical-stage pharma company developing PP2A inhibitors to…
|
LIXT | US | Professional, scientific and te… |
|
Lunai Bioworks Inc.
Pre-clinical biotech company using AI for drug discovery an…
|
RENB | US | Professional, scientific and te… |
|
LYSOGENE
A former clinical-stage biotech that developed gene therapi…
|
LYS | FR | Professional, scientific and te… |
|
MaaT Pharma
A clinical-stage biotech developing microbiome-based therap…
|
MAAT | FR | Professional, scientific and te… |
|
Many Bright Ideas Technologies Inc.
Acquires, develops, and commercializes IP, emphasizing alte…
|
MBI.H | CA | Professional, scientific and te… |
|
MapLight Therapeutics, Inc.
Develops targeted therapies for CNS disorders using circuit…
|
MPLT | US | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.